Introduction

Hepatitis B virus (HBV) infection is one of the most serious and prevalent public health problems. Approximately 257 million people are chronically infected with HBV, resulting in 887,000 deaths in 2015, mostly from complications of acute or chronic HBV infection, including liver cirrhosis and hepatocellular carcinoma [1]. To date, 10 distinct HBV genotypes (A–J) with different geographical distributions have been identified. Genotypes A and D are widespread in Africa and Europe; genotypes B and C are prevalent in Asia; and genotypes E–J are occasionally encountered in Europe, America, and Asia. Genotypes A–D are most prevalent and are responsible for approximately 90% of hepatitis B cases globally [2].

The HBV envelope contains small (S), middle (M), and large (L) proteins. PreS1 of the L protein contains a receptor-binding motif crucial for HBV infection. This motif is highly conserved among 10 HBV genotypes (A–J), making it a potential target for the prevention of HBV infection. In this study, we successfully generated a neutralizing human monoclonal antibody (mAb), 1A8 (IgG1), that recognizes the receptor-binding motif of preS1 using a phage-displayed human synthetic Fab library. Analysis of the antigen-binding activity of 1A8 for different genotypes indicated that it can specifically bind to the preS1 of major HBV genotypes (A–D). Based on Bio-Layer interferometry, the affinity ($K_D$) of 1A8 for the preS1 of genotype C was 3.55 nM. 1A8 immunoprecipitated the hepatitis B virions of genotypes C and D. In an in vitro neutralization assay using HepG2 cells overexpressing the cellular receptor sodium taurocholate cotransporting polypeptide, 1A8 effectively neutralized HBV infection with genotype D. Taken together, the results suggest that 1A8 may neutralize the four HBV genotypes. Considering that genotypes A–D are most prevalent, 1A8 may be a neutralizing human mAb with promising potential in the prevention and treatment of HBV infection.

Keywords: Hepatitis B virus, preS1, human monoclonal antibody, phage display, synthetic antibody library, neutralizing antibody
Particles consist mainly of S proteins and typically outnumber virions by 1,000:1 to 10,000:1. Thus, these particles have been suspected to reduce the virus-specific immune response by mimicking virions [4]. Unlike S protein, the preS1 of L protein exists primarily in infectious virions. In addition, amino acids 20–26 of preS1 play an essential role in the interaction with the cellular receptor sodium taurocholate cotransporting polypeptide (NTCP) and mediate HBV infection [5, 6]. This essential region is highly conserved among HBV genotypes (Fig. 1), making it a potential target for the prevention and treatment of HBV infection.

Hepatitis B immunoglobulin (HBIG) is currently used as a post-exposure prophylactic medical treatment for accidental or perinatal HBV exposure. HBIG is prepared by collecting the serum of high anti-S protein antibody titers. Considering that the preS1 region is crucial for HBV infection, a preS1-specific monoclonal antibody (mAb) may represent a promising approach for the prevention and treatment of HBV infection. Clinically, the appearance of anti-preS1 antibodies in patients correlates well with better recovery from acute hepatitis B [7]. To date, several anti-preS1 mAbs with HBV-neutralizing activity in vivo or in vitro have been generated by immunizing mice with HBV particles or recombinant preS1 antigen (mAb) may represent a promising approach for the prevention and treatment of HBV infection. Clinically, the appearance of anti-preS1 antibodies in patients correlates well with better recovery from acute hepatitis B [7]. To date, several anti-preS1 mAbs with HBV-neutralizing activity in vivo or in vitro have been generated by immunizing mice with HBV particles or recombinant preS1 antigen [8–14]. However, most of the antibodies do not neutralize all of the HBV genotypes. Therefore, we aimed to generate mAbs against the highly conserved essential region of preS1 for more effective prevention strategies. In the present study, using a phage-displayed human synthetic Fab library, we describe the successful generation of a human mAb, 1A8, which binds to the highly conserved receptor-binding motif of preS1 and neutralizes HBV infection in vitro.

Materials and Methods

Cell Culture

Suspension-adapted HEK293F cells (Invitrogen, USA) were grown in FreeStyle 293 Expression medium (Gibco, USA) at 125 rpm and 37°C in a humidified incubator with 8% CO₂. Human hepatoma HepG2 cells were grown in DMEM (Gibco, USA) supplemented with 10% fetal bovine serum (GE Healthcare Life Sciences, USA) at 37°C in a humidified incubator with 5% CO₂.

Preparation of PreS1 Antigens

GST-preS1(1–119), GST-preS1(1–56), and preS1(1–119) of HBV genotype C were prepared as described previously [15]. The recombinant preS1 of HBV genotypes A–G, comprising the Ig1–5 domains of human L1 cell adhesion molecule (L1CAM), preS1(1–60), and Strep tag, was transiently expressed in HEK293F cells for 7 days and purified by affinity chromatography using a Strepactin Superflow high capacity column (Iba, Germany) as described previously [9]. Biotinylated synthetic preS1 peptide (biotin–SGSGNPLGFFPDHQLDP, Bio-preS1-L peptide) containing the NTCP-binding motif (20–NPLGFFP–26) with >98% of purity was purchased from AnyGen, Inc. (South Korea). The recombinant preS1 antigens and Bio-preS1-L peptide were used as antigens for biopanning and enzyme-linked immunosorbent assay (ELISA).

Selection of PreS1-Specific Fab from a Phage-Displayed Human Synthetic Fab Library

A human synthetic Fab library (1.35 × 10⁹ diversity, unpublished) constructed in our laboratory was panned against the four preS1 antigens GST-preS1(1–119), GST-preS1(1–56), Bio-preS1-L peptide, and preS1(1–119), for the first, second, third, and fourth rounds, respectively, using the standard panning procedure [16]. Briefly, an immunotube (or streptavidin-coated plates in the case of Bio-preS1-L peptide) was coated with each preS1 antigen at 4°C overnight. Antibody library phages were incubated with the antigen and unbound phages were washed out with 0.1% PBST.
(0.1% Tween 20 in PBS). The bound phages were eluted using 10 μg/ml trypsin solution at 37°C for 30 min. *Escherichia coli* TG1 cells (OD$_{600}$ ~0.5) were infected with the eluted phages, grown for 1 h at 37°C, plated on a 2× YT/carbenicillin/glucose agar plate, and incubated overnight at 37°C. The amplified phages were subjected to the next round of panning, with the washing stringency increased gradually at each round (Fig. 2A). For titration, the number of input and output phages for each panning round was calculated by dilutions and colony-forming units. After the four rounds of panning, the output cells were grown and infected with helper phages to obtain polyclonal Fab phages. These phages were subjected to indirect ELISA to confirm the enrichment of positive clones. After the fourth round of panning, a total of 188 colonies were randomly selected and individually grown as monoclonal Fab phages.

**Conversion of Fab into IgG1 and Expression in HEK293F Cells**

To convert the selected Fab into IgG1 format, the heavy chain variable region (VH) and kappa light chain variable region (VK) sequences were amplified by PCR and combined with the IgG heavy and light chain leader sequences, respectively, using recombinant PCR. The resulting VH and VK sequences were subcloned into the EcoRI-ApaI and HindIII-BsiWI sites of the pdCMV-dhfrC expression plasmid containing the human Cγ1 and Cκ genes, respectively. The resulting expression plasmids were introduced into HEK293F cells using polyethyleneimine (linear 25 kDa; Polysciences, USA) at a ratio of 1:4 (60 μg:240 μg) as described previously [18]. The transfected cells were cultured for 7 days and the culture supernatants filtered using a bottle top filter (0.22 μm PES; Sartorius, Germany) for antibody purification.

**Purification of Anti-PreS1 Human mAb**

The culture supernatants were subjected to affinity chromatography on Protein A-agarose beads (Amicogen, Korea) as described previously [9]. The antibody concentration was determined by a NanoDrop 2000 UV-Vis Spectrophotometer (Thermo Fisher Scientific, USA). The integrity and purity of the purified antibody were assessed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).

**Analysis of Antigen-Binding Activities of Purified 1A8 mAb**

To analyze the antigen-binding activities of the purified 1A8 mAb to the preS1 antigens of different HBV genotypes, the
DNA was detected as described previously [20]. Briefly, the immunoprecipitated complex three times with PBS, the viral cells and 10 μg of purified GST-preS1(1–56) were separated by 12% SDS-PAGE, transferred to a nitrocellulose membrane, and immunocomplex was treated with DNase I (Sigma, USA) and mung bean nuclease (Takara, Japan) at 37°C for 20 min to remove transfected plasmid DNA. The core-associated HBV DNA was prepared by digestion with Proteinase K (20 mg/ml; Roche, USA) at 37°C for 2–3 h in the presence of 0.5% SDS. HBV DNA was extracted using phenol/chloroform/isoamyl alcohol (25:24:1) (Sigma, USA) and precipitated with ethanol and 3 M sodium acetate. The purified DNA was separated on a 1% agarose gel, and HBV DNA was detected by Southern blot hybridization using a 32P-labeled HBV probe [20, 22].

**In Vitro HBV Neutralization Assay**

The HBV-neutralizing activity of 1A8 was investigated using a HepG2-NTCP stable cell line. The HepG2-NTCP cells were seeded at a density of 6 × 10^4 cells in 6-well plates and cultured at 37°C. The next day, the HepG2-NTCP cells were infected with HBV particles of genotype D (~2,000 viral genome equivalents per cell) in primary hepatocyte maintenance medium (PMM) containing 4% PEG and 2.5% DMSO as described previously [20]. For the neutralization assay, the HBV particles were pre-incubated with each antibody at different concentrations for 1 h at room temperature and then added to the cultured HepG2-NTCP cells. The medium was changed every 2 days for PMM supplemented with 2.5% DMSO, and the infected cells were harvested 7 days post-infection. The intracellular HBV DNA was extracted from the infected HepG2-NTCP cells and subjected to Southern blot hybridization.

**Results**

**Isolation of Fabs Specific to HBV PreS1 from a Phage Antibody Library**

To isolate Fabs specific to preS1 of HBV, a phage-displayed human synthetic Fab library (1.35 × 10^9 diversity, unpublished) was panned against four preS1 antigens: GST-preS1(1–119), GST-preS1(1–56), Bio-preS1-L peptide, and preS1(1–119) [15]. The output phage titers increased after the third round of panning against the Bio-preS1-L peptide (Fig. 2A), and the antigen-binding activity of polyclonal output phages to preS1 antigens increased significantly, as assessed by indirect ELISA (Fig. 2B). After the fourth round of panning, 188 phage Fab clones were randomly selected and their antigen-binding activities analyzed by indirect ELISA using preS1(1–119), Bio-preS1-L peptide, and recombinant preS1 of genotypes A and D. The 1A8 phage Fab had the highest antigen-binding activity with preS1 and was selected for further study (Fig. 2C).

**Conversion of 1A8 Fab into Human IgG1 and Analysis of Its Antigen-Binding Activity**

The 1A8 Fab was converted into human IgG1 and

### In Vitro HBV Neutralization Assay

The HBV-neutralizing activity of 1A8 was investigated using a HepG2-NTCP stable cell line. The HepG2-NTCP cells were seeded at a density of 6 × 10^4 cells in 6-well plates and cultured at 37°C. The next day, the HepG2-NTCP cells were infected with HBV particles of genotype D (~2,000 viral genome equivalents per cell) in primary hepatocyte maintenance medium (PMM) containing 4% PEG and 2.5% DMSO as described previously [20]. For the neutralization assay, the HBV particles were pre-incubated with each antibody at different concentrations for 1 h at room temperature and then added to the cultured HepG2-NTCP cells. The medium was changed every 2 days for PMM supplemented with 2.5% DMSO, and the infected cells were harvested 7 days post-infection. The intracellular HBV DNA was extracted from the infected HepG2-NTCP cells and subjected to Southern blot hybridization.

**Results**

**Isolation of Fabs Specific to HBV PreS1 from a Phage Antibody Library**

To isolate Fabs specific to preS1 of HBV, a phage-displayed human synthetic Fab library (1.35 × 10^9 diversity, unpublished) was panned against four preS1 antigens: GST-preS1(1–119), GST-preS1(1–56), Bio-preS1-L peptide, and preS1(1–119) [15]. The output phage titers increased after the third round of panning against the Bio-preS1-L peptide (Fig. 2A), and the antigen-binding activity of polyclonal output phages to preS1 antigens increased significantly, as assessed by indirect ELISA (Fig. 2B). After the fourth round of panning, 188 phage Fab clones were randomly selected and their antigen-binding activities analyzed by indirect ELISA using preS1(1–119), Bio-preS1-L peptide, and recombinant preS1 of genotypes A and D. The 1A8 phage Fab had the highest antigen-binding activity with preS1 and was selected for further study (Fig. 2C).

**Conversion of 1A8 Fab into Human IgG1 and Analysis of Its Antigen-Binding Activity**

The 1A8 Fab was converted into human IgG1 and
transiently expressed in HEK293F cells, and the culture supernatants were subjected to protein purification. The integrity and purity of purified 1A8 IgG1 were confirmed by SDS-PAGE (Fig. 3A). The purified 1A8 bound to the recombinant preS1 of genotypes A–D; its antigen-binding activity to genotypes A–C was the same and approximately 35% higher than to genotype D (Fig. 3B). However, 1A8 hardly bound to preS1 of genotype E, and did not bind to genotypes F and G. In addition, the antigen-binding activity of 1A8 to preS1(1-119) of genotype C was slightly lower than that of HzKR127-3.2 [8], a humanized anti-preS1 mAb with a $K_D$ of 0.5 nM (Fig. 3C). Affinity determination by BLI using Octet RED indicated that the $K_D$ of 1A8 for the recombinant preS1 of genotype A was approximately 3.55 nM (Fig. 3D).

Validation of the Antigen-Binding Specificity of 1A8
To evaluate the antigen-binding specificity of 1A8, GST-preS1(1–56) was expressed in E. coli DH5a and the lysates of uninduced or induced cells were subjected to western blot analysis for 1A8, with purified GST-preS1(1–56) as a positive control. As shown in Fig. 4, 1A8 exhibited antigen-binding specificity to preS1 without any nonspecific binding activity to endogenous protein of E. coli.

Evaluation of the HBV-Neutralizing Activity of 1A8
Prior to assessing the in vitro HBV-neutralizing activity of 1A8, an immunoprecipitation assay was performed to determine whether 1A8 can bind the hepatitis B virion. A previously developed HBV-neutralizing humanized anti-preS1 mAb, HzKR127-3.2, was used as a positive control for HBV genotypes C and D, whereas the humanized anti-preS1 mAb HzKR359-1 was used as a positive control for genotype C and a negative control for genotype D [8, 9]. Mouse IgG was used as a negative control. Viral DNA was extracted from immunoprecipitates and measured by
Southern blot hybridization. As shown in Fig. 5A, the relaxed circular (RC) and double-stranded linear (DSL) forms of HBV DNA were detected in 1A8 precipitates, indicating that 1A8 could bind to both HBV genotypes C and D.

To examine whether 1A8 can neutralize HBV infection, HBV particles of genotype D were pre-incubated with each antibody at different concentrations, and then added to cultured HepG2-NTCP cells overexpressing the cellular receptor NTCP. At 7 days post-infection, the infected cells were harvested and the intracellular HBV DNA was measured by Southern blot hybridization. Although 1A8 had a lower binding activity to preS1 of genotype D than to that of genotype C (Fig. 3B), it effectively neutralized infection with both HBV genotypes in a dose-dependent manner (Fig. 5B). The neutralizing efficacy was similar to that of HzKR127-3.2, which has a higher affinity than 1A8. This result is consistent with the immunoprecipitation assay.

**Discussion**

PreS1 of HBV contains a highly conserved receptor-binding motif that plays an essential role in and mediates HBV infection. However, HBIG, which is currently used as a post-exposure prophylactic medical treatment, contains mostly anti-S protein antibodies. The subviral particles are usually present in 10,000-fold excess over complete HBV particles in the blood of infected persons. Therefore, mAbs targeting the receptor-binding motif of preS1 may represent a promising approach for the effective prevention and treatment of HBV infection. In this study, we successfully generated a broadly neutralizing human mAb specific to the receptor-binding motif by panning a phage-displayed human synthetic Fab library against preS1 antigens comprising the short peptide containing the receptor-binding motif. Analysis of the antigen-binding activity indicated that 1A8 can bind to the preS1 of four major HBV genotypes (A–D). In addition, 1A8 bound the HBV particles of both genotypes C and D and effectively neutralized infection with HBV of genotype D in vitro. The results suggest that 1A8 may neutralize HBV genotypes A–D. Given that these genotypes are responsible for approximately...

**Fig. 4.** Western blot analysis of 1A8 mAb. GST-preS1(1–56) was expressed in *E. coli* DH5a and subjected to 12% SDS-PAGE (left) followed by western blot analysis with 1A8 (right). M, protein marker; lane 1, uninduced cell lysates; lane 2, IPTG-induced cell lysates; lane 3, purified GST-preS1(1–56) with the molecular mass of 34 kDa.

**Fig. 5.** Evaluation of the virion-binding activity and in vitro virus-neutralizing activity of 1A8 against HBV of genotype D. (A) Immunoprecipitation of HBV particles (genotypes C and D) by 1A8. HzKR127-3.2 was used as a positive control for genotypes C and D, whereas HzKR359-1 was used as a positive control for genotype C and a negative control for genotype D. Mouse IgG was used as a negative control for both genotypes. RC DNA, relaxed circular DNA; DSL DNA, double-stranded linear DNA. (B) HBV particles (genotype D) were pre-incubated with 1A8 or HzKR127-3.2 (10, 1, and 0.1 µg), and then added to cultured HepG2-NTCP cells. The medium was changed every 2 days and infected cells were harvested at 7 days post-infection. The intracellular HBV DNA was extracted and subjected to Southern blot hybridization.

---

Anti-Hepatitis B Virus PreS1-Neutralizing Human Monoclonal Antibody 1381

August 2018 | Vol. 28 | No. 8
90% of hepatitis B cases globally [2], 1A8 may represent a neutralizing human mAb that can be used for the prevention and treatment of HBV infection.

Regarding the epitope of 1A8, it exhibited reduced binding activity towards preS1 of genotypes D or E compared with genotypes A–C, indicating that the amino acid at position 19 influences the antigen-binding activity of 1A8, and that Pro19 is optimal for antigen binding. In addition, 1A8 did not exhibit antigen-binding activity toward preS1 of genotypes F or G, indicating that Phe25 is essential for antibody binding. The results suggest that 1A8 recognizes amino acids 20–25 in the receptor-binding motif and, thus, neutralizes HBV infection by blocking the preS1-NTCP interaction.

To date, several murine anti-preS1 mAbs with HBV-neutralizing activity in vivo or in vitro have been reported, but these antibodies exhibit limited neutralizing activities against some HBV genotypes, in addition to the immunogenicity issue [12-14]. In our previous study, we developed HBV-neutralizing humanized anti-preS1 mAb HzKR127-3.2 and HzKR359-1 [8, 9]. HzKR127-3.2 exhibited binding activity only to preS1 of genotypes A, C, D, and G, whereas HzKR359-1 bound to genotypes A, B, and C. To our best knowledge, 1A8 is the first human anti-preS1 mAb that may neutralize the four major HBV genotypes (A–D). Considering that the presence of anti-preS1 antibodies in patients correlates with better recovery from acute hepatitis B, and that antibody-mediated immunotherapy could be effective for chronic hepatitis B [7, 23], 1A8 may be effective in the prevention of HBV infection and as a therapy for hepatitis B.

Acknowledgments

This work was supported by a grant (C1011479-01-03) from the Ministry of Science, ICT and Future Planning.

Conflict of Interest

The authors have no financial conflicts of interest to declare.

References


